The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Self-citationReubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Self-citationLamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Reubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Self-citation99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals
Liu, S., & Edwards, D. S. (1999) · Chemical Reviews · doi:10.1021/cr980436l · Cited by 511
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Self-citationTumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Gibril, F., Reynolds, J. C., Doppman, J. L., Chen, C. C., Venzon, D. J., Termanini, B., Weber, H. C., Stewart, C. A., & Jensen, R. T. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00005 · Cited by 440
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Self-citationYttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Heppeler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., & Hennig, M. (1999) · Chemistry - A European Journal · doi:10.1002/(sici)1521-3765(19990702)5:7<1974::aid-chem1974>3.0.co;2-x · Cited by 337
Self-citationYttrium-90-labelled somatostatin-analogue for cancer treatment
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E., Herrmann, R., & Maecke, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78355-0 · Cited by 335
Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
Heppeler, A., Froidevaux, S., Eberle, A., & Maecke, H. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003374516 · Cited by 258
Lebtahi, R., Cadiot, G., Sarda‐Mantel, L., Daou, D., Faraggi, M., Petegnief, Y., Mignon, M., & Guludec, D. L. (1997) · PubMed · Cited by 240
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
Krenning, E. P., de Jong, M., Kooij, P. P. M., Breeman, W. A. P., Bakker, W. H., de Herder, W. W., van Eijck, C. H. J., Kwekkeboom, D. J., Jamar, F., Pauwels, S., et al. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_2.s23 · Cited by 234
Self-citationBreeman, W. A., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W. H., Kooij, P. P., Visser, T. J., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100502 · Cited by 226
Self-citationde Jong, M., Bakker, W. H., Krenning, E. P., Breeman, W. A. P., van der Pluijm, M. E., Bernard, B. F., Visser, T. J., Jermann, E., Béhé, M., Powell, P., et al. (1997) · European Journal of Nuclear Medicine · doi:10.1007/bf00881807 · Cited by 215
Self-citationEisenwiener, K.-P., Prata, M. I. M., Buschmann, I., Zhang, H.-W., Santos, A. C., Wenger, S., Reubi, J. C., & Mäcke, H. R. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010074f · Cited by 213
Self-citation[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy
de Jong, M., Breeman, W. A. P., Bernard, B. F., Bakker, W. H., Schaar, M., van Gameren, A., Bugaj, J. E., Erion, J. L., Schmidt, M. A., Srinivasan, A., et al. (2001) · International Journal of Cancer · Cited by 210
Self-citationTermanini, B., Gibril, F., Reynolds, J., Doppman, J., Chen, C., Stewart, C., Sutliff, V., & Jensen, R. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024287 · Cited by 206
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
Paganelli, G., Zoboli, S., Cremonesi, M., Bodei, L., Ferrari, M., Grana, C., Bartolomei, M., Orsi, F., De Cicco, C., Mäcke, H. R., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100490 · Cited by 206
Self-citationNeuropeptide receptors in health and disease: the molecular basis for in vivo imaging.
Reubi, J. C. (1995) · PubMed · Cited by 198
Self-citationChiti, A., Fanti, S., Savelli, G., Romeo, A., Bellanova, B., Rodari, M., van Graafeiland, B. J., Monetti, N., & Bombardieri, E. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050314 · Cited by 168
A ticket to ride: peptide radiopharmaceuticals.
Fischman, A. J., Babich, J. W., & Strausś, H. W. (1993) · PubMed · Cited by 155
Cremonesi, M., Ferrari, M. E., Zoboli, S., Chinol, M., Stabin, M. G., Orsi, F., Maëcke, H. R., Jermann, E., Robertson, C., Fiorenza, M., et al. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050462 · Cited by 148
Gibril, F., Doppman, J. L., Reynolds, J. C., Chen, C. C., Sutliff, V. E., Yu, F., Serrano, J., Venzon, D. J., & Jensen, R. T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1040 · Cited by 142
Raulf, F., Pérez, J., Hoyer, D., & Bruns, C. (2009) · Digestion · doi:10.1159/000201201 · Cited by 136
de Jong, M., Breeman, W. A. P., Bernard, B. F., Bakker, W. H., Visser, T. J., Kooij, P. P. M., van Gameren, A., & Krenning, E. P. (2001) · PubMed · Cited by 102
Self-citationA new peptidic somatostatin agonist with high affinity to all five somatostatin receptors
Reubi, J. C., Eisenwiener, K., Rink, H., Waser, B., & Mäcke, H. R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02651-1 · Cited by 91
Self-citationLebtahi, R., Cloirec, J. L., Houzard, C., Daou, D., Sobhani, I., Sassolas, G., Mignon, M., Bourguet, P., & Guludec, D. L. (2002) · PubMed · Cited by 89
DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy1
Smith-Jones, P. M., Bischof, C., Leimer, M., et al. (1999) · Endocrinology · doi:10.1210/endo.140.11.7126 · Cited by 85
Fates of endocytosed somatostatin sst2 receptors and associated agonists
Koenig, J., Kaur, R., DODGEON, I., Edwardson, J. M., & Humphrey, P. P. A. (1998) · Biochemical Journal · doi:10.1042/bj3360291 · Cited by 61
Froidevaux, S., Heppeler, A., Eberlé, A. N., Meier, A.-M., Häusler, M., Beglinger, C., Béhé, M. P., Powell, P., & Mäcke, H. R. (2000) · Endocrinology · doi:10.1210/endo.141.9.7683 · Cited by 60
Self-citationCadiot, G., Bonnaud, G., Lebtahi, R., Sarda‐Mantel, L., Ruszniewski, P. B., Guludec, D. L., & Mignon, M. (1997) · Gut · doi:10.1136/gut.41.1.107 · Cited by 52
Established Clinical Use of Octreotide and Lanreotide in Oncology
Öberg, K. (2001) · Chemotherapy · doi:10.1159/000049160 · Cited by 43
Cited by
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Self-citationVirgolini, I., Ambrosini, V., Bomanji, J. B., Baum, R. P., Fanti, S., Gabriel, M., Papathanasiou, N. D., Pepe, G., Oyen, W., De Cristoforo, C., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1512-3 · Cited by 442
Chong, W. H., Molinolo, A. A., Chen, C. C., & Collins, M. T. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0006 · Cited by 429
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Metadata
- Authors
- Wild, D., Schmitt, J. S., Ginj, M., Mäcke, H. R., Bernard, B. F., Krenning, E., de Jong, M., Wenger, S., & Reubi, J.-C.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2003-08-21
- Volume
- 30
- Issue
- 10
- Pages
- 1338-1347
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2088147866
- Cited by
- 310
- References
- 37
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.